Is tpst stock good to buy right now

Tempest Therapeutics (TPST) stock does not appear to be a good buy at the moment. Here's why:

1. Recent Surge in Stock Price: TPST stock has seen a significant increase, with a 44.8% rise on the day of the announcement of new data from the Phase 1b/2 clinical trial of amezalpat. This is largely due to investor excitement over the six-month improvement in median overall survival advantage shown by amezalpat when combined with atezolizumab and bevacizumab.

2. Technical Indicators Suggest Caution: The stock's technical indicators show a 5-day moving average of $2.16, a 10-day moving average of $2.18, and a 50-day moving average of $3.10. The RSI is at 24.85, which is considered to be in the oversold territory but also suggests that the stock may be undervalued. The MACD is -0.07, indicating a bearish trend, and the Bollinger Bands show a lower band at 2.66, which could be a support level.

3. Financial Performance: The company has reported a net loss of $7.9 million and a negative ROE of -33.35% as of the last quarter. This financial performance indicates that the company is currently unprofitable and may not be in a strong financial position.

4. Analyst Price Targets: Analysts have set a 12-month price target for TPST at an average of $21.68, with a high estimate of $49.35. However, it's important to note that these targets are based on projections and may not always be accurate.
5. Market Sentiment: The sentiment around TPST is generally bearish, with a fear and greed index of 39 (Fear) and a recent stock forecast predicting a drop in price. This suggests that investors may be cautious or pessimistic about the stock's future performance.

In conclusion, while the recent positive data from the clinical trial could be a positive sign, the current surge in stock price, combined with the bearish technical indicators and the company's financial performance, suggests that TPST stock may not be a good buy at the moment. Investors should exercise caution and consider these factors before making any investment decisions.